

ELAINE VICKERS

A BEGINNER'S GUIDE TO

TARGETED CANCER TREATMENTS

WILEY Blackwell

A Beginner's Guide to Targeted Cancer Treatments

A Beginner's Guide to Targeted Cancer Treatments

Elaine Vickers, PhD

Science Communicated Ltd

WILEY Blackwell

This edition first published 2018
© 2018 by John Wiley & Sons Ltd

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Elaine Vickers to be identified as the author in this work has been asserted in accordance with law.

Registered Office(s)

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office

9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Vickers, Elaine (Elaine Ruth), author.

Title: A beginner's guide to targeted cancer treatments / by Elaine Vickers.

Description: Hoboken, NJ : Wiley, 2018. | Includes bibliographical references and index. |

Identifiers: LCCN 2018000469 (print) | LCCN 2018000728 (ebook) | ISBN 9781119126836 (pdf) | ISBN 9781119126829 (epub) | ISBN 9781119126799 (pbk.)

Subjects: | MESH: Neoplasms--drug therapy | Molecular Targeted Therapy--methods

Classification: LCC RC271.C5 (ebook) | LCC RC271.C5 (print) | NLM QZ 267 | DDC 616.99/4061--dc23

LC record available at <https://lcn.loc.gov/2018000469>

Cover Design: Wiley

Cover Images: (Sphere bacteria cells) © neyro2008/Gettyimages;
(Antibodies attacking cancer cells) © Eraxion/Gettyimages

Set in 9.5/13pt Palatino by SPi Global, Pondicherry, India

Contents

Acknowledgments, vii
About the Author, ix
How to Use This Book, xi

CHAPTER 1 An Introduction to Cancer Cell Biology and Genetics, 1

- 1.1 Introduction, 1
- 1.2 DNA Damage is the Cause of Every Cancer, 2
- 1.3 The Defining Features (Hallmarks) of Cancer Cells, 15
- 1.4 Genetic Variation among Cancer Cells in a Single Tumor, 16
- 1.5 The Cancer Microenvironment, 17
- 1.6 Cancer Spread/Metastasis, 19
- 1.7 Cancer Stem Cells, 23
- 1.8 Obstacles That Prevent us from Curing Cancer, 24
- 1.9 Final Thoughts, 28

CHAPTER 2 Introducing Targeted Cancer Treatments, 33

- 2.1 Introduction, 34
- 2.2 Monoclonal Antibodies, 36
- 2.3 Kinase Inhibitors, 48
- 2.4 Final Thoughts, 60

CHAPTER 3 Treatments That Block Proteins Involved in Cell Communication, 65

- 3.1 Introduction, 65
- 3.2 Introducing Growth Factor Receptors, 67
- 3.3 Drugs That Target EGFR, 75
- 3.4 Drugs That Target HER2, 81
- 3.5 Drugs That Block Other Growth Factor Receptors, 85
- 3.6 Introduction to Signaling Pathways as a Target for Cancer Therapy, 86
- 3.7 Targeting the MAPK Signaling Pathway, 87
- 3.8 Targeting the PI3K/AKT/mTOR Signaling Pathway, 94
- 3.9 Targeting the JAK-STAT Pathway, 100
- 3.10 Final Thoughts, 103

- CHAPTER 4** **Drugs That Target: Angiogenesis, Fusion Proteins, PARP, Hedgehog Signaling, and CDKs, 111**
- 4.1 Angiogenesis Inhibitors: Introduction, 112
 - 4.2 Drugs That Block Fusion Proteins: Bcr-Abl, ALK, RET, and ROS1, 122
 - 4.3 PARP Inhibitors, 127
 - 4.4 Hedgehog Pathway Inhibitors, 134
 - 4.5 Cyclin-Dependent Kinase (CDK) Inhibitors, 139
 - 4.6 Final Thoughts, 145
- CHAPTER 5** **Immunotherapies for Cancer, 151**
- 5.1 Introduction, 152
 - 5.2 A Bit About Cancer and the Immune System, 154
 - 5.3 Checkpoint Inhibitors, 160
 - 5.4 Adoptive Cell Transfer, 168
 - 5.5 Modified Bi-specific Antibodies, 175
 - 5.6 Therapeutic Cancer Vaccines, 176
 - 5.7 The Future of Immunotherapy, 181
- CHAPTER 6** **Targeted Treatments for Common Solid Tumors, 187**
- 6.1 Introduction, 188
 - 6.2 Targeted Treatments for Breast Cancer, 188
 - 6.3 Targeted Treatments for Prostate Cancer, 200
 - 6.4 Targeted Treatments for Lung Cancer, 204
 - 6.5 Targeted Treatments for Bowel Cancer, 214
 - 6.6 Targeted Treatments for Malignant Melanoma Skin Cancer, 220
 - 6.7 Targeted Treatments for Kidney Cancer, 225
 - 6.8 Targeted Treatments for Head and Neck Cancer, 231
 - 6.9 Targeted Treatments for Brain Tumors, 235
 - 6.10 Targeted Treatments for Bladder Cancer, 236
 - 6.11 Targeted Treatments for Pancreatic Cancer, 240
 - 6.12 Final Thoughts, 244
- CHAPTER 7** **Targeted Treatments for Hematological Cancers, 259**
- 7.1 Introduction, 259
 - 7.2 A Bit About Hematological Cancers, 260
 - 7.3 Antibody-Based Treatments That Target CD Antigens, 274
 - 7.4 Drugs That Block B Cell Receptor Signaling, 287
 - 7.5 Bcr-Abl Inhibitors, 292
 - 7.6 Drugs That Block the Proteasome, 294
 - 7.7 Thalidomide and its Derivatives, 297
 - 7.8 JAK2 Inhibitors, 298
 - 7.9 Bcl-2 Inhibitors, 299
 - 7.10 FLT3 and KIT Inhibitors, 301
 - 7.11 IDH2 Inhibitors, 304
 - 7.12 CAR-Modified T Cell Therapy, 304
 - 7.13 Final Thoughts, 304

Appendix, 313

Glossary of Terms, 315

Index, 329

Acknowledgments

I would like to thank Heather Phillips, Sue Bailey, and Carrie Weller for their generous support and encouragement over many years, and for providing advice and feedback on the contents of this book.

Thanks also go to the people (nurses, doctors, pharmacists, trials coordinators, and others) who read through various chapters and provided valuable comments and suggestions. They are Maggie Uzzell, Anne Croudass, Dan Collins, Ben Hood, Kate Searle, Nikki Hayward, Richard Berks, Sandra Gutchner, Sue

Brook, Tom Taylor, Jo Bird, Zahid Bashir, Kate Montague-Hellen, Alasdair Rankin, and Jean Tremlett.

A special thanks goes to Ruth McLaren, who first suggested I should teach nurses and who made it possible. I would also like to thank her for inspiring me to make cancer education my full-time occupation.

Finally, I would like to thank my parents for their unending love, and my husband Rowan, for always listening and for being hugely enthusiastic about everything I do.

About the Author



Elaine Vickers has worked as a science educator and writer for over fifteen years. Since setting up her company, Science Communicated Ltd. (www.sciencecommunicated.co.uk), she has created numerous study days and modules

that explain the science behind targeted cancer treatments. Each year, she teaches hundreds of cancer nurses, doctors, and clinical research staff in hospitals and research centers throughout the United Kingdom. She is also the author and presenter of “Demystifying Targeted Cancer Treatments,” an online course commissioned by Cancer Research UK. Elaine has a degree in Medical Science from the University of Birmingham and a PhD in Molecular Biology from the University of Manchester. Her goal is to unravel the complexities of cancer biology and new cancer treatments, and to make these topics interesting and accessible to non-scientists. She loves hiking and going to the ballet, and considers herself incredibly lucky to live in Manchester with her husband Rowan.

How to Use This Book

I have written *A Beginner's Guide to Targeted Cancer Treatments* because I couldn't find a resource that described how new cancer treatments worked without relying on vague generalizations or that didn't overwhelm the reader with scientific detail.

Every year, I teach hundreds of nurses, trials coordinators, pharmacists, and others involved in the delivery of cancer clinical trials and treatments. I felt I owed it to the people I teach to provide a resource that would avoid unnecessary jargon and be written in the same everyday language that I use to teach. I also wanted to give readers access to some of the illustrations I have developed during my years of teaching.

As you'll quickly realize, although I have called this book "A beginner's guide ..." I do include a lot of science. I also don't try to hide the complexity of the subject I am attempting to describe. However, I hope that by including a general overview of cancer biology in Chapter 1, and an overview of monoclonal antibodies and kinase inhibitors in Chapter 2, you'll feel prepared for the later chapters.

You'll also notice that I don't describe any advances in radiotherapy or surgery. These omissions are because I'm a molecular biologist and don't feel qualified to stray into other disciplines. I have also not covered any advances made in the design or use of chemotherapy. This is partly because chemotherapies are relatively untargeted, and also

because I presumed that my readers would already have a reasonable idea as to how they work. If you're looking for information on hormone therapies, you'll find it in Chapter 6, when I discuss treatments for breast cancer and prostate cancer. Also, what I can't do in this book is to pass on any medical or practical knowledge of the treatments I write about, because I have none. So if you're looking for information about the best course of treatment for a patient, or for practical advice, that information will need to come from elsewhere.

One problem I had when writing this book is the rapid pace of cancer research and drug development. For example, when I first started writing back in January 2015, just one checkpoint inhibitor (ipilimumab) was licensed in the United States and Europe to treat one type of cancer, malignant melanoma. But now, in December 2017, four checkpoint inhibitors are licensed in Europe, five in the United States, and they're used to treat people with a wide range of solid tumors and Hodgkin lymphoma. Thus, although I have done my best to make this book up to date, this up-to-dateness will be quickly eroded by the creation of new treatments and new approvals in the months and years to come. Despite this, I hope that because I have focused on the mechanisms of action of new treatments, rather than their stage of development, you will find this book relevant to you.

When writing, I have presumed that you will be coming at this subject area from one of four angles:

1. Because you've heard about **a particular treatment** and want to learn more about it – in which case you might want to start with the index and go from there.
2. Because you're involved in the care of people affected by **a particular type of cancer**, and you want to know about the treatments that are relevant to them – in which case you might be best off navigating to the section about that cancer in Chapter 6 or 7.
3. Because you've heard about **a group of treatments**, such as CDK inhibitors or checkpoint inhibitors, and you want to know how they work – in which case Chapter 3, 4, or 5 might be your starting point.
4. Because you're working in clinical trials or on wards in which you come into contact with **various new treatments**, and you want to know more about how all these treatments work – in which case you might want to start at the beginning!

Whatever your reason for reading this book, my sincere hope is that you will find it useful.

CHAPTER 1

An Introduction to Cancer Cell Biology and Genetics

IN BRIEF

It is impossible to describe targeted cancer treatments without mentioning what it is they target. And when I try to explain what it is they target, I find myself going back to the beginning and explaining where cancers come from, what faults they contain, and why they behave as they do. And in order to explain that, I need explain concepts such as different types of DNA damage, oncogenes and tumor suppressor genes, and the hallmarks of cancer cells.

Hence, in this chapter, I provide an overview of the causes and consequences of DNA mutations in cells. And I describe how even just a handful of key mutations can force a healthy cell to become a cancer cell.

I also describe the cancer microenvironment – the cells and structures that cancer cells live among. Cancer cells have the ability to exploit their microenvironment and in many instances manipulate it. I explain what impact this has when doctors come to treat people with the disease.

In addition, I tackle topics such as genomic instability and intratumoral heterogeneity. Perhaps these are topics that right now don't mean anything to you, and you're unsure of why you need to know about them. But it's only through understanding these concepts that you can appreciate the limitations of targeted (and standard) cancer treatments and the promise of immunotherapy. It is also important to understand why cancer spreads and how cancers evolve and change over time.

Finally, I wrap up the chapter with a brief overview of why cancer is so difficult to treat successfully and why so many people currently cannot be cured.

1.1 INTRODUCTION

This book is all about the science behind targeted cancer treatments. And, almost without exception, **all targeted cancer treatments work by targeting proteins** that are either inside or on the surface of cancer cells or the

cells around them. So in order to explain how targeted cancer treatments work, I need to describe the proteins found in cancer cells and how they differ from those in healthy cells. In order to do this, I need to explain the different types of DNA damage that cancer cells contain, **because a cell's DNA is its instruction**

manual telling it how to make proteins. If we know what DNA damage a cell contains, this will tell us what faulty proteins it's making. And if we know what faulty proteins it's making, we will know which targeted treatments might work against it.

A general understanding of the DNA damage that cancer cells contain, and what impact this has on cancer cells, should help you make sense of why some treatments are applicable to some cancer patients and not others. It should also help you understand why it can be helpful to test a patient's cancer cells for the presence or absence of various DNA mutations.

So **this chapter is all about cancer cells, DNA, and proteins.** And, along with the chapter that follows (which is all about the two main groups of targeted cancer treatments: monoclonal antibodies and kinase inhibitors), this chapter will hopefully provide you with all the background information you need to make sense of the rest of the book.

However, even in this chapter, I've made some assumptions about what you do and don't know. For example, I've assumed that you have a rough idea of what DNA is and how cells use their DNA to make proteins. I'm also assuming that you know what proteins are and a bit about what some of them do. If you're not familiar with these concepts, I would recommend first of all taking a look at the Appendix, which contains a list of reading material about cells, DNA, chromosomes, genes, and proteins. When you've had a look at that, you'll be ready to read further.

1.2 DNA DAMAGE IS THE CAUSE OF EVERY CANCER

Our cells' DNA is essentially a huge instruction manual telling our cells what proteins to make, how to make them, when to make

them, what to do with them, and when to destroy them. In turn, the proteins our cells make dictate their behavior. For this reason, **if you damage a cell's DNA, you also end up with damaged proteins**, leading to abnormal behavior.

A cancer starts to develop when a single cell accumulates DNA damage that causes it to make various faulty proteins that force it to behave abnormally. This normally doesn't happen. **A cell that finds its DNA is damaged usually either tries to repair the damage, or it self-destructs** through a process called apoptosis.¹ But, if a cell doesn't notice the damage and survives and later accumulates more damage, it might ultimately become a cancer cell.

Over the past 40 years or so, scientists have been gradually discovering what DNA damage cancer cells contain and how this affects their proteins. The scientists' primary focus has been to study the DNA that contains the instructions to make proteins – our cells' genes. This protein-coding DNA only takes up about 1% or so of our cells' total DNA [1]. (What exactly the other 99% of our cells' DNA is for is a matter of continued debate among scientists.)

Through initiatives such as The Cancer Genome Atlas [2] and the International Cancer Genome Consortium [3], hundreds of scientists have amassed an incredible catalog of information about the thousands of different DNA mutations cancer cells contain [4]. They've also discovered that **different types of cancer differ from one another in terms of the mutations they contain and the treatments they respond to.** And as well as the differences, we know that important similarities can exist between cancers that arise in different organs. For example, some breast cancer patients may have tumors that overproduce² a protein called HER2, as do the tumors of some patients with stomach cancer [5].

¹ Apoptosis is also referred to as "programmed cell death."

² Scientists generally talk about proteins being "over-expressed" rather than "overproduced," but they essentially mean the same thing.

Box 1.1 The names of genes and their proteins

As you read this book you might notice that protein names are written normally but that gene names are written in *italics*. For example, the *HER2* gene contains the instructions for making HER2 protein. You might also notice that sometimes the gene and protein have different names. An example of this is the *TP53* gene, which contains the instructions for making a protein called p53. It's also possible for a gene to contain the instructions for making more than one protein. For instance, the *CDKN2A* gene (sometimes referred to as the *CDKN2A* locus) contains the instructions for making several proteins, two of which are called p16^{INK4a} and p14^{ARF}.

To add to the confusion, some genes and proteins have more than one name. For example, the *HER2* gene is also called *ErbB2* and *NEU*. The reasons behind the various names often have a lot to do with what organism or group of cells the gene/protein was discovered in; if it's similar to another gene/protein that has already been discovered; what role the gene/protein is thought to play in the cells or organism it was found in; and whether or not abnormalities in the gene/protein cause disease. For example, *HER2* stands for human epidermal growth factor receptor-2, because it's similar in structure to *HER1* (although we usually refer to *HER1* as the EGF-Receptor). *HER2* is also called *ErbB2* because a very similar gene, called *Erb-b*, was discovered in a disease-causing virus called the avian erythroblastosis virus. And *HER2* is also called *NEU* because a faulty version of it can cause a cancer called neuroblastoma in rodents.

A final point to note is that gene names are often written in capital letters, whereas protein names aren't. But this convention isn't always adhered to.

Because there is lots to say about the DNA mutations in cancer cells, I'm going to split it up into different topics. First, I'll talk about what **causes the DNA mutations** found in cancer cells (Section 1.2.1). Then I'll describe what **types of mutation** occur (see Section 1.2.2), how the **number of mutations** in cancer cells varies (see Section 1.2.3), and **which mutations have the greatest effect on cell behavior** (see Section 1.2.4). Then I'll talk about some of the most **common gene mutations** in cancer cells and what impact they have (Section 1.2.5).

Later in the chapter, we will look at the defining **characteristics of cancer cells** (Section 1.3), how cancer cells in a tumor can be **genetically different from one another**

(Section 1.4); how they **interact with and influence the non-cancer cells** that live alongside them (Section 1.5), and how they **invade and spread** (Section 1.6).

All of this information is gradually helping scientists create new, more targeted cancer treatments, which are the subject of the rest of this book.

1.2.1 Causes of DNA Mutations

There are many different reasons why our cells' DNA gets damaged. Some of this damage is **natural and unavoidable**, whereas some of it is down to our **lifestyle, behaviors, exposures, geographical location**, and even **local customs**.³ We can also **inherit** DNA damage from our parents. Depending on

³ For example, in countries like Iran, people are used to drinking much hotter tea than people do in the United Kingdom, and this has been linked to a higher incidence of esophageal cancer.

what sort of data scientists look at (e.g., whether they examine individual cells or whole organs or tissues, or look at populations of people in different countries), they end up drawing very different conclusions about what proportion of cancers could be avoided [6]. So although I've listed some of the causes of DNA damage below, I haven't tried to pin down exactly how many cancers are caused by each one.⁴

Where DNA Damage Comes from – Lifestyle and Exposures

Cells that are exposed to high levels of **carcinogens** (anything that causes cancer is called a carcinogen) are particularly vulnerable to becoming cancer cells. This includes cells that line our lungs, skin, bowel, and stomach. Carcinogens include various constituents of cigarette smoke, alcohol, sunlight, radiation from X-rays, some viruses, asbestos, and food toxins [7, 8].

Our cancer risk is also linked to our **diet** (including our consumption of fruit and vegetables, red and processed meat, high salt intake, and low fiber), our level of **physical activity**, and our **weight**. This is a huge topic. If you would like to read more, I suggest looking at the Cancer Research UK [9, 10] and American Cancer Society [11] websites.

Where DNA Damage Comes from – Inherited Mutations

Some people are **born with DNA faults** that put them at higher risk of cancer than the people around them. Sometimes the fault has been passed down from generation to generation, with many family members affected. For example, actress and film director Angelina Jolie has inherited a fault in one copy of her

BRCA1 gene. Because this fault is shared by many of her relatives, she lost her mother, grandmother, and aunt to cancer [12]. Faults in high-risk genes such as *BRCA* genes are generally rare, but they can have an enormous impact on a person's cancer risk. More commonly, subtle variations in many genes will combine to affect our risk.

Faults can also arise in a mother's egg or a father's sperm. If the faulty egg or sperm goes on to create an embryo, this fault will be present in every cell. Or, the fault might occur later, as the growing embryo is developing. For example, faults that occur in an embryo's white blood cells as its immune system forms can cause infant or childhood leukemia [13].

Where DNA Damage Comes from – Chemical Reactions

Unfortunately for us, **our cells' DNA gets damaged every second of every day** – it is estimated that even without the influence of external factors like diet, smoking, or sunlight, each of our cells sustains damage to its DNA roughly 20,000 times each day [14].

Much of this damage is caused by the products of chemical reactions that are essential to keep us alive. For example, many of our cells' important chemical reactions produce oxygen free radicals⁵ – high-energy oxygen atoms that essentially bash into and break DNA [15]. Our cells contain well over 100 different DNA repair proteins to fix this damage [16]. But sometimes they fail to spot all the damage, or they simply can't keep up.

Where DNA Damage Comes from – DNA Polymerase

Tissues that need to renew and replenish their cells often (such as the lining of our bowel, our

⁴ If you do want to learn more about what you can do to reduce your risk, I would recommend looking at the Cancer Research UK website: <http://www.cancerresearchuk.org/about-cancer/causes-of-cancer/can-cancer-be-prevented>.

⁵ These are also called reactive oxygen species – ROS.

skin, and immune system) are the most at risk of cancer [17–19].⁶ This is because for a cell to multiply, it has to make a complete copy of all of its DNA – all 3,000 million base pairs of it [20]. The enzyme that copies DNA, called DNA polymerase, although spectacularly fast and accurate, does occasionally make mistakes [21]. Therefore, **cells that have to multiply often are at a greater risk of becoming cancer cells** than cells that rarely, if ever, multiply.

Where DNA Damage Comes from – APOBEC Enzymes

APOBEC⁷ enzymes are a family of proteins that our cells use to help protect them from virus infections. **APOBEC enzymes attack viruses** by introducing mutations into their DNA. However, if an uninfected cell accidentally makes APOBEC enzymes, the enzymes will attack the cell's own DNA and introduce lots of mutations that could cause cancer [22]. Also, even when the cell has become a cancer cell, APOBEC enzymes continue to add more and more damage to the cell's genes [23].

Where DNA Damage Comes from – Cancer Treatments

Most **chemotherapies and radiotherapy work by causing so much DNA damage** that cancer cells die. However, not every cell is killed. Cells that sustain damage to their DNA and yet survive may later become cancer cells. Because of this, people treated for cancer sometimes develop second cancers months or even many years later.

The Influence of Sex Hormones

When discussing the causes of cancer, we shouldn't ignore the influence of sex hormones such as **estrogen, progesterone, and testosterone**. These tiny, fat-soluble chemicals encourage cells that contain receptors for them to survive, grow, and multiply (estrogen can also cause DNA damage [24]). Cancers that develop from hormone-sensitive tissues in the breast and prostate often retain their sensitivity to hormones. These cancers respond to treatments that block the production of hormones in the body or that block the impact of hormones on cancer cells.

In women, the risk of various cancers, including breast, ovarian, and endometrial cancer, is linked to their body's exposure to sex hormones such as estrogen. Reproductive factors (such as age of menarche⁸ and menopause, along with the number of pregnancies and length of time they breast-fed) and bodyweight affect their lifetime exposure to estrogen and thus also influence their cancer risk.

The Influence of Inflammation

For many people, their cancer diagnosis was preceded by **years of inflammation, infection, or irritation** [25]. For example, people with chronic hepatitis B or hepatitis C are at high risk of liver cancer, whereas people with inflammatory bowel disease are at an increased risk of bowel cancer [25]. It seems that the presence of white blood cells in a tissue can increase the DNA mutation rate in the tissues' cells and encourage the cells to multiply, raising the risk of cancer [26].

⁶ If this seems like a simple and straightforward association, don't be fooled. There is huge controversy around the exact relationship between cancer risk and tissue renewal, number of stem cells, and DNA damage by environmental versus natural mechanisms. I've supplied a handful of references if you want to explore further.

⁷ In case you're curious, APOBEC stands for apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like.

⁸ The age at which a girl has her first period.

The Influence of Epigenetics

Epigenetics refers to chemical changes to the DNA double helix and to histone proteins that DNA wraps around [27, 28]. Epigenetic changes don't alter the sequence of the four bases in DNA. But **epigenetic changes do affect how compact and tightly coiled DNA is**. This in turn affects whether the information in genes is accessible to the cell's transcription factors and whether the genes can be used to make proteins. For example, if a stretch of DNA in a chromosome is very compact, it won't be transcribed. But if it's relaxed, it's available for transcription. The pattern of epigenetic changes in our DNA appears to be partly inherited from our parents, but it may also be affected by inflammation, exposure to some chemicals, nutrition, and our own and possibly even our parents' lifestyles. Epigenetics is also affected by many of the gene mutations found in cancer cells [29].

Causes of DNA Mutations – Summary

Our risk of cancer in any particular place in our body is therefore a combination of:

- Our age
- The natural rate that the cells multiply in that tissue
- The extent to which DNA polymerase, oxygen free radicals, and APOBEC enzymes have caused mutations in the tissue's cells (the amount of damage will gradually increase as we age)
- Our sex, our lifestyle, and behaviors (which will be hugely impacted by our cultural background, physical location, and personal choices and opportunities)
- Our cells' exposure to carcinogens, hormones, and factors that cause inflammation
- Our inherited genetic and epigenetic makeup

Cancer Research UK estimates that **around 42% of cancers are potentially preventable** through changes to lifestyle, behaviors, exposures, and weight [30, 31]. However, we

cannot influence factors such as the activity of APOBEC enzymes or the accuracy of DNA polymerase. As I said before, estimating what proportion of cancers can be prevented is an incredibly contentious topic, and estimates vary widely depending on how the research was done.

1.2.2 Types of DNA Mutations

As we've seen, DNA damage is caused by a wide variety of different factors. Some causes of damage are natural and unavoidable, and others are potentially avoidable.

DNA mutations also come in many forms. For the sake of simplicity, I'm going to split them into two groups: (1) mutations affecting long stretches of DNA and whole chromosomes and (2) mutations affecting just a few DNA base pairs.

Mutations Affecting Long Stretches of DNA and Whole Chromosomes

For a start, **many cancers are aneuploid** – that is, the cells contain the wrong number (i.e., not the normal 23 pairs) of chromosomes [32]. However, although this is no doubt important, it's not always clear what impact this is having on the cell. Because the detection of extra chromosomes in cancer cells doesn't generally help doctors decide what treatment to use, I'm not going to talk about this further.

What can be more helpful is detecting chromosome faults such as translocations, inversions, insertions, deletions, and amplifications.

Chromosome Translocations and Rearrangements

A chromosome translocation is when two chromosomes break, and the cell accidentally sticks them back together incorrectly (see Figure 1.1). Chromosomal rearrangements are similar, but both breaks occur in a single chromosome. More often than not, the




Figure 1.1 A chromosome translocation. Two chromosomes (colored turquoise and orange) break. The cell accidentally sticks them back together incorrectly. If the chromosomes have broken where genes are located, this may result in the creation of a gene fusion.

chromosomes break in regions that don't contain any genes (remember that the information to make proteins only takes up 1% or so of our chromosomes). However, **sometimes translocations and rearrangements do affect genes**, and this can have dire consequences. For example, the cancer cells of chronic myeloid leukemia (CML) almost always contain a translocation in which chromosome 9 and chromosome 22 have broken and been stitched back together incorrectly. This causes the *BCR* gene on chromosome 22 to become fused together with the *ABL* gene on chromosome 9 [33]. The fusion of these two genes forces the cell to make a Bcr-Abl **fusion protein** (a protein made from the information in the fusion gene), which forces the cells to grow and multiply.

In other cancers, you find translocations and rearrangements in which a control region from one gene (a promoter or enhancer⁹) has become fused to the protein-coding region¹⁰ of

a second gene. This has often happened during the development of prostate cancer and some forms of blood cancer such as non-Hodgkin lymphomas and multiple myeloma. In prostate cancer, the rearrangement often involves the *ERG* and *TMPRSS2* genes on chromosome 21. The rearrangement places the promoter from the *TMPRSS2* gene (a gene which is always active in prostate cells) next to the protein-coding region from a powerful, pro-growth protein called *ERG* [34] (see Figure 1.2). The consequence of this rearrangement is the massive overproduction of ERG protein, which forces the prostate cell to multiply.

Chromosome Insertions

This occurs when **part of one chromosome is inserted into another chromosome** (Figure 1.3). It can also occur when part of a chromosome is re-inserted back into the chromosome it came from, but in the wrong place. An example is the “internal tandem duplications” affecting the *FLT3* gene that are found in the cancer cells of around a third of people with acute myeloid leukemia (AML) [35]. The insertion involves part of the *FLT3* gene, which is copied and re-inserted back into the gene. This causes the cell to make an extra-large, overactive version of FLT3 protein. FLT3 inhibitors are in clinical trials. (See Chapter 7, Section 7.10.1 and Figure 7.21 for more about FLT3 mutations in AML.)

Chromosome Deletions

Not surprisingly, a chromosome deletion is when **part of a chromosome gets deleted** (Figure 1.4a). Examples include deletion of the part of chromosome 17 that contains the *TP53* gene, and deletion of the part of chromosome 9 containing the *CDKN2A* gene. Both *TP53*

⁹ The Khan Academy website has a nice description of gene regulation: <https://www.khanacademy.org/science/biology/gene-regulation/gene-regulation-in-eukaryotes/a/overview-of-eukaryotic-gene-regulation>.

¹⁰ That is, the part of the gene that contains the instructions to make a protein.




Figure 1.2 The TMPRSS2-ERG gene fusion found in prostate cancer cells. (a) In healthy prostate cells, androgen receptors pair up due to the presence of testosterone. Paired-up receptors then attach to the TMPRSS2 gene promoter and cause the cell to produce TMPRSS2 protein. (b) In contrast, prostate cells only rarely produce ERG, because the ERG gene does not contain attachment sites for androgen receptors. (c) 50% of prostate cancers contain a chromosome rearrangement which puts the protein-coding region of the ERG gene under the control of the promoter from the TMPRSS2 gene. This mutation causes the cell to produce ERG, which in turn forces the cell to multiply.

and *CDKN2A* are vital tumor suppressor genes that prevent our cells from becoming cancer cells (there is more about *TP53* and *CDKN2A* in Section 1.2.5). Their loss means




Figure 1.3 A chromosome insertion – part of one chromosome is inserted into another chromosome (as shown) or back into the same chromosome but in the wrong location.

that part of the cell's protection against cancer has gone.

Chromosome Inversions

Inversions (Figure 1.4b), in which part of a chromosome is cut out, flipped over, and then re-inserted, can also disrupt genes. For example, an inversion of part of chromosome 2 is found in about 4% of non-small cell lung cancers (this is the most common type of lung cancer). The inversion joins together the *ALK* gene with part of the *EML4* gene, creating an uncontrollable fusion protein that forces the cells to multiply [36]. Three ALK inhibitors are now licensed treatments for ALK-mutated lung cancers; they are crizotinib (Xalkori), alectinib (Alacensa), and ceritinib (Zykadia). (For more about ALK mutation in lung cancer, and ALK inhibitors, see Chapter 4, Section 4.2.4 and Chapter 6, Section 6.4.4.)




Figure 1.4 Chromosome deletions and inversions. (a) In a chromosome deletion, part of a chromosome is (not surprisingly) deleted. An example is the deletion of part of chromosome 17 containing the *TP53* gene in chronic lymphocytic leukemia, bowel cancer, and other cancers. (b) **Chromosome inversion** – a segment of the chromosome is cut out, flipped over, and inserted back into the chromosome; for example, inversions involving the *ALK* gene on chromosome 2 in lung cancer.

Gene Amplification

Lastly, one of the most commonly looked for types of chromosome damage is gene amplifications. Gene amplifications occur when a cell's DNA replication machinery **accidentally makes extra copies of a region of a chromosome** that contains one or more genes (see Figure 1.5). As a consequence, the cell overproduces (over-expresses) the proteins made from the amplified genes. A common amplification is that of the *HER2* gene (the *HER2* gene is also commonly called *Neu* or *ErbB*), which is amplified in about 18%–20% of breast cancers [37].

Point Mutations

A point mutation is when **one DNA base is accidentally added, deleted, or swapped** for a different one. Most point mutations have no impact on the cell as they occur outside of genes. However, if a point mutation (such as




Figure 1.5 Gene amplification. The cell accidentally makes extra copies of part of a chromosome. The duplicate segments are inserted into other chromosomes or back into the same chromosome; for example, amplification of a segment of chromosome 17 containing the *HER2* gene in breast cancer.

a base substitution, addition, or deletion) occurs within a gene, it can have various consequences (see Figure 1.6).¹¹ Point mutations are classed as missense, nonsense, or silent, depending on what consequence the mutation has on protein production. They are also classified as “in-frame” or “frameshift” mutations.

Missense Mutations

If one DNA base is substituted for a different one, this might mean that the **protein made from that gene differs by one amino acid** from the normal protein (three DNA bases in a gene equate to one amino acid in the resulting

¹¹ If you need a refresher on gene transcription and translation at this point, I suggest taking a look at some of the resources suggested in the Appendix.




Figure 1.6 Point mutations. A point mutation (shown by a red star) is when one DNA base is added, deleted, or swapped for a different one in the cell's DNA (a). If the mutation is in a gene, the mutation will be copied into the mRNA (b) and it may alter the resulting protein. The consequence might be that (c) due to a **missense mutation**, the protein made by the cell differs from the normal (the so-called “wild-type”) version of the protein by one amino acid, (d) a **nonsense mutation** in the DNA introduces a stop signal into the mRNA, and the cell makes an extra-short (truncated) protein, (e) a **silent mutation** has no impact on the protein produced, (f) a **frameshift** mutation causes the cell to make a very different protein compared to the normal protein, one which is only partly the same as the original.

protein) (Figure 1.6c) [38]. Two examples are the faulty version of the B-Raf protein (called V600E), which is often found in the cancer cells of people with malignant melanoma, and some of the faulty versions of EGFR (epidermal growth factor receptor), which are found in the cancer cells of some people with lung cancer. In both cases, the faulty proteins (both of which contain hundreds of amino acids) are just one amino acid different from the healthy version of the protein. However, even changing that one amino acid is sufficient to create a massively overactive version of B-Raf or EGFR.

Nonsense Mutations

Nonsense mutations are those that cause the cell to make **a shortened (truncated) version of the protein** (Figure 1.6d). This happens because the change to the DNA sequence creates a “stop codon” in the resulting mRNA strand. As you might already know, proteins are made from 20 different amino acids, and

each set of three bases (called a codon) in the mRNA strand tells the ribosome what amino acid to add next to the protein it's making.¹² But there are three codons (UAA, UAG, and UGA) which tell the ribosome to stop adding any more amino acids. If a DNA point mutation creates one of these stop codons part way through the mRNA from a gene, then the ribosome will stop part way through making the protein. For example, some of the inherited *BRCA* gene mutations that increase a woman's risk of breast and ovarian cancer cause her cells to produce a shortened version of a *BRCA* protein [39].

Silent Mutations

These point mutations **don't have any impact on the protein** the cell makes even if they occur within a gene (Figure 1.6e). For example, if a ribosome comes across the mRNA sequence CCC, this tells it to add a proline amino acid to the protein it's making. If a point mutation

¹² If you're struggling to make sense of this, I would suggest looking at the Appendix and learning a bit about gene transcription and translation.

changes the mRNA from CCC to CCA, this has no impact because the sequence CCA also tells the ribosome to add a proline.

In-Frame and Frameshift Mutations

If one or two DNA bases are added or deleted to a gene's sequence, this can create a frameshift mutation that has an enormous impact on what protein is produced (Figure 1.6f). An example is if one DNA base is added to a gene that changes the mRNA from ...CGACGACGA... to ...CCGACGACGA... Now, instead of reading the sequence as ...CGA CGA CGA... adding three arginine amino acids to the protein, the ribosome reads ...CCG ACG ACG A... and adds a proline followed by two threonines. The ribosome carries on going from there, adding a completely different selection of amino acids from the normal selection. As a result, **the protein the cell makes may bear very little resemblance to the normal protein**. Frameshift mutations also commonly introduce stop codons that create truncated proteins.

An "in-frame" mutation is opposite to a frameshift mutation – that is, it is a mutation that either swaps one base for a different one, or one in which bases are added in multiples of three, so they don't alter the rest of the protein made. For example, if three bases are added to ...CGACGACGA... so that it becomes ...CGA**CCC**CGACGA..., the ribosome will insert an extra proline in between the arginines, but it has no further impact on the rest of the protein.

1.2.3 Numbers and Patterns of DNA Mutations in Cancer Cells

In recent years, technologies have been developed that allow scientists to pinpoint the location of thousands of DNA mutations inside cancer cells. They have discovered that **different cancers contain different numbers, types, and patterns of mutations that arise due to**

different mutational processes. For example, lung cancers from smokers contain lots of point mutations in which a C has been changed to an A. A different pattern of mutations – where there are lots of insertions and deletions of more than three DNA bases at a time – is common in people with cancers associated with inherited *BRCA* gene mutations. Other patterns are linked to overactive APOBEC enzymes. In all, scientists have so far discovered 30 different patterns of mutations, which they call "mutation signatures" [40]. And, of course, it's possible for one cancer cell to contain multiple patterns of mutations because the cancer has arisen due to a combination of causes.

The amount of damage in cancer cells' DNA varies greatly from cancer type to cancer type [41]. For example, cancers that have come about because of the effects of powerful carcinogens often contain a vast amount of DNA damage. Therefore, lung cancers in people who smoke or have smoked in the past contain ten times the number of mutations as lung cancers in people who have never smoked. Malignant melanoma skin cancers, which are almost always caused by UV light from the sun, also contain a vast number of mutations [41]. In general, cancers in older people contain more mutations than those in children and young adults. Older peoples' cells have simply had many more years in which to accumulate mutations.

Although cancer cells often contain hundreds or even thousands of mutations, the majority of these mutations have no discernible impact on the cell's behavior. They have occurred because the cancer cell is damaged and unstable and is picking up new mutations all the time. The mutations that are important in driving the cancer cells' abnormal behavior are referred to by scientists as **driver mutations**. Mutations that add little or nothing to the cells' behavior are called **passenger mutations**.

Perhaps not surprisingly, scientists are much more interested in finding a cancer's driver mutations than its passenger mutations. They want to know what's driving the cells' behavior so that they can do something about it.

1.2.4 Driver Mutations – Those That Affect Cancer Cell Behavior

In order for DNA damage to cause cancer, some of it must occur in genes that control the cell's behavior. These “driver mutations” affect cell processes and behaviors such as:

- How fast the cell grows
- How frequently it multiplies
- The way it communicates with neighboring cells
- How often and how well it checks its own health
- Its ability to survive in adverse conditions such as low oxygen levels
- Its ability to move through the body's tissues
- Whether it goes through all the normal checks and balances during the cell cycle¹³
- Whether it still has the ability to self-destruct
- The way it produces energy
- Whether it can hide from or suppress the person's immune system

The genes that have caused these changes in behavior are classed as oncogenes, tumor suppressor genes, and DNA repair genes.

Oncogenes

Many of the proteins made from these genes encourage our cells **to survive, grow, and multiply**. Others can make cells more **mobile and invasive** or help them to **hide from the immune system**. All these genes need to be tightly controlled to avoid cancer. In cancer cells, they're damaged in a way that they're overproduced and/or overactive. Examples

of oncogenes include *EGFR*, *RAS*, *B-RAF*, *MYC*, *HER2*, and *SRC*.

Tumor Suppressor Genes

The proteins made from these genes **slow down or stop cell growth and proliferation and trigger cell death (apoptosis)**. In cancer cells, they're damaged in a way that causes their protection to be lost. Examples include *TP53*, *PTEN*, *RB1*, and *APC*.

DNA Repair Genes

The proteins made from these genes **sense and repair DNA damage**. In cancer cells, they're damaged in such a way that they can no longer do their job properly. Because of this, cancer cells pick up more and more DNA damage as time goes on. Examples of DNA repair genes include *BRCA1*, *BRCA2*, *ATM*, *ATR*, *RAD51*, and *ERCC1*.

In healthy cells, the proteins made from DNA repair genes keep the cell's DNA free from faults. There is also a balancing act between the oncogenes and the tumor suppressor genes. For example, a protein called Bcl-2 protects cells from death, whereas a protein called p53 triggers death. The gene for making Bcl-2 (called *BCL2*) is an oncogene; the gene for making p53 (called *TP53*) is a tumor suppressor gene. Healthy cells contain strict amounts of both proteins that balance each other out. But cancer cells often contain too much Bcl-2 and too little, or faulty, p53.

Multiple Driver Mutations Are Necessary for a Cell to Become a Cancer Cell

The sequence of events that leads to bowel cancer is often given as an example of how the gradual accumulation of mutations in several oncogenes, tumor suppressor genes, and DNA repair genes can ultimately cause someone to develop cancer.

¹³ The cell cycle is the normal, step-by-step process our cells go through when they multiply.

Our bowel is lined by orderly layers of cells known as epithelial cells. Because bowel cells are constantly getting scraped off by food passing through, our bowel cells have to multiply pretty often in order to keep the number of cells constant. Cells that multiply are prone to picking up mutations. So our bowel cells tend to contain more and more mutations as we get older. If a mutation affects a gene called *APC*, this is bad news as *APC* is an important tumor suppressor gene. But the situation isn't desperate as it's only one mutation, which isn't enough to cause cancer. However, if it's followed by a mutation in *KRAS*, then the situation becomes worse; *KRAS* is a powerful growth-promoting oncogene that forces the cell to multiply more rapidly. As the cells multiply, they pick up yet more mutations. The cell still isn't a cancer cell because other protective proteins are still doing their job. But if genes such as *PIK3CA* (an oncogene), *SMAD4* (a tumor suppressor gene), and *TP53* (a tumor suppressor gene) become faulty, then the cell will become a full-blown cancer cell [41] (see Figure 1.7 for an illustration of this process).

In other cancers, a similar **combination of mutations in a handful of important genes** is thought to drive their behavior [42].

1.2.5 The “Usual Suspects” – Genes Commonly Mutated in Many Cancers

Some gene mutations are common only in one or two types of cancer. These include the *VHL* mutations that are very common in kidney cancer and some of the translocations that are very common in hematological cancers (such as leukemias, lymphomas, and multiple myeloma). But **other gene mutations crop up time and time again** in many different cancer types. I'll be mentioning some of these gene mutations again and again in this book, so I've listed a handful of them in Table 1.1 to give you a rough idea of what they do.

One thing that might (or might not!) jump out at you from the table is that that many of the most commonly mutated genes in cancer cells are involved in **cell communication pathways**. These pathways are used by all our




Figure 1.7 The series of mutations leading to many bowel cancers. (a) Orderly, well-connected cells line the bowel. (b) A random mutation in a bowel cell lead to loss of *APC* activity; this cell starts to multiply slightly faster than its neighbors, forming a little lump – an adenoma. The faulty cells are not yet cancer cells, but because they are multiplying more quickly than normal, they are prone to collecting more mutations. (c) Weeks, months, or years later, a mutation in the *KRAS* gene causes the K-Ras protein to become overactive; the cells now multiply rapidly and in a disorderly fashion. (d) Finally, genes like *TP53*, *PIK3CA*, and *SMAD4* are mutated. The faulty cells are now full-blown cancer cells, able to invade through local tissues and spread to other parts of the body.

Abbreviations: *APC* – adenomatous polyposis coli; *TP53* – tumor protein 53; *PIK3CA* –phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; *SMAD4* – SMAD family member 4

Table 1.1 A selection of some of the most commonly mutated oncogenes, tumor suppressor genes, and DNA repair genes in human cancers.

<i>Gene name</i> (protein name)	What protein is made from this gene?	What is the consequence for the cell if the gene is mutated?
Oncogenes		
RAS (Ras)	The three Ras proteins (K-Ras, N-Ras, and H-Ras) are enzymes involved in cell communication. There are three versions of the gene (<i>KRAS</i> , <i>NRAS</i> , and <i>HRAS</i>), which contain the instructions for making the three proteins [43].	All the proteins made from these genes are involved in cell communication pathways – the sequences of events triggered inside a cell when it receives a signal to grow and multiply from its neighbors. Therefore, all these proteins cause cells to grow and multiply. Overactive communication pathways also force cells to survive (even when damaged) and to become more mobile and invasive.
PIK3CA (p110-alpha)	The PI3K protein is an enzyme involved in cell communication. It comes in many different forms and is made up of two component parts: an enzyme part and a regulatory part. The <i>PIK3CA</i> gene encodes an enzyme part called p110alpha (p110 α) [44].	For more on cell communication pathways and how they work, see Chapter 3, Section 3.2.
HER2/NEU/ERBB2 (HER2)	A receptor found on the cell surface; it activates cell communication pathways inside the cell [45].	
MYC (MYC)	A transcription factor – it attaches to various gene promoters and triggers gene transcription. Many of the genes it controls are involved in cell growth and proliferation [46].	
BRAF (B-Raf)	An enzyme involved in cell communication and activated by Ras proteins [47].	
EGFR (EGFR)	A receptor found on the cell surface; it activates cell communication pathways inside the cell [45].	
Tumor suppressor genes		
TP53 (p53)	A transcription factor activated by DNA damage and other triggers – it attaches to various gene promoters and triggers gene transcription. The proteins produced as a result of p53 block cell proliferation and cause cell death [48].	If p53 is not working properly or is missing from a cell, the cell loses the ability to stop multiplying or die in response to DNA damage.
PTEN (PTEN)	An enzyme involved in cell communication that blocks the activity of PI3K. PTEN also helps cells avoid DNA damage [49].	If PTEN is not working properly or is missing from a cell, the PI3K-controlled communication pathway becomes overactive.
RB (RB)	It has a pocket in it that fits E2F proteins, which control entry into the cell cycle ^a . RB holds onto and blocks E2F proteins, and this prevents the cell from entering the cell cycle [50].	If RB is not working properly or is missing from a cell, E2F can force the cell into the cell cycle (for more about RB and E2F, see Chapter 4, Section 4.5).
CDKN2A (p16 INK4a)	p16 ^{INK4a} is a protein that blocks a set of enzymes called the CDKs. The CDKs force RB to let go of E2F proteins (see the description of RB above). Hence, p16 prevents cells from entering the cell cycle (see Chapter 4, Figures 4.18 and 4.19) [50].	If p16 ^{INK4a} is not working properly or is missing from a cell, E2F can force the cell into the cell cycle.
NF1 (neurofibromin)	A large protein that inactivates Ras proteins (see the description of Ras earlier in this table) [51].	If neurofibromin is not working properly or is missing from a cell, Ras proteins become overactive.
APC	The surface of the APC protein has various different regions through which it interacts with many different proteins involved in cell communication, mobility, adhesion to neighboring cells, and other processes [52].	If APC is not working properly or is missing from a cell, then levels of another protein, beta-catenin (β -catenin), rise. Beta-catenin causes cells to multiply.

Table 1.1 (Continued)

DNA repair genes		
BRCA1 (BRCA1) & BRCA2 (BRCA2)	BRCA1 and BRCA2 are both necessary for a DNA repair process called homologous recombination (HR). Our cells use HR to accurately repair double-strand breaks in their DNA (see Chapter 4, Section 4.3. for more information on BRCA proteins).	If either BRCA1 or BRCA2 is not working properly or is missing from a cell, the cell can no longer perform HR. It is therefore liable to pick up lots of DNA mutations.
ATM & ATR	These are enzymes whose activity is triggered when a cell detects that its DNA is damaged. They coordinate the cell's response to the damage [53].	If either ATM or ATR is damaged or missing from a cell, its ability to respond to DNA damage is compromised.

Abbreviations: *PIK3CA* – phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; *HER2* – human epidermal growth factor receptor-2; *EGFR* – epidermal growth factor receptor; *TP53* – tumor protein p53; *PTEN* – phosphatase and tensin homologue; *RB* – retinoblastoma protein; *NF1* – neurofibromatosis type 1; *APC* – Adenomatous polyposis coli; *BRCA* – Breast cancer susceptibility gene; *ATM* – ataxia-telangiectasia mutated; *ATR* – ATM- and Rad3-Related

^a The cell cycle is the very orderly and precise sequence of events that a cell goes through in order to multiply.

Source: Kandoth C et al. (2013). Mutational landscape and significance across 12 major cancer types. *Nature* **502**: 333–339.

body's cells to sense and respond to: changes in their environment, signals sent out by neighboring cells, the presence or absence of hormones, and signals sent out by white blood cells. A wide variety of communication pathways exist in our cells. And there are some proteins like Ras and PI3K that are involved in many different signaling pathways. These pathways are often the target of new cancer drugs, and the whole of Chapter 3 is dedicated to explaining them and the cancer drugs that block them.

1.3 THE DEFINING FEATURES (HALLMARKS) OF CANCER CELLS

All cancers are presumed to begin with a single cell that has sustained damage to its DNA and has multiplied out of control. As an adult, it's probably true that every cell in our body contains some sort of damage to its DNA.

However, what sets a cancer cell apart from a non-cancer cell is:

- The **amount** and **type** of DNA damage the cells contain
- The **location** of this damage in oncogenes, tumor suppressor genes, and DNA repair genes
- The **changes in behavior** that the damage causes

The behavioral changes that set a cancer cell apart from a healthy cell are collectively known as “**the hallmarks of cancer**.” Six hallmarks were listed and described by two scientists called Douglas Hanahan and Robert Weinberg back in 2000 [54], and they added two more in 2011 [55]. I've described all eight below.

1.3.1 The Eight Hallmarks of Cancer

1. **They can tell themselves to multiply.** A normal cell only multiplies when it receives an instruction¹⁴ to do so. A cancer cell can generate those instructions itself.

¹⁴ This instruction is usually in the form of small proteins known as “growth factors” released by the cells' near neighbors – see Chapter 3, Section 3.2.1 for more on this.

2. **They are insensitive to negative feedback**, because proteins that would normally tell them to stop multiplying and die (like p53) have been lost or don't work properly.
3. **They resist death**. Every day, millions of cells in our body self-destruct because they have worn out or become damaged. Cancer cells have defects that make it almost impossible for them to do this.
4. **Cancer cells can multiply forever** because they contain a protein called telomerase. Healthy cells lack this protein and eventually stop multiplying.
5. **They gain a blood supply**. Cancer cells release a tiny protein called VEGF that tells nearby blood vessels to sprout and grow (a process called **angiogenesis**). New blood vessels supply the growing cancer with oxygen and nutrients.
6. **They can invade and spread**. Most of our body's cells are connected to each other in orderly arrangements. Cancer cells have lost connective proteins from their surface, and they are independent and mobile.
7. **They have changed the way they produce energy**. Healthy cells use sugars from our food to make energy using a highly efficient, oxygen-dependent process. Cancer

cells use an inefficient process that requires less oxygen but helps them multiply more quickly.

8. **They can avoid destruction by the immune system**. White blood cells constantly patrol our body looking for defective cells. Cancer cells hide from white blood cells; suppress cancer-fighting white blood cells; co-opt white blood cells for their own purposes (there is lots more about this in Chapter 5 on immunotherapy).

1.4 GENETIC VARIATION AMONG CANCER CELLS IN A SINGLE TUMOR

A major reason why many tumors fail to respond to treatment or become resistant later is **intratumoral heterogeneity** – the fact that inside a tumor there are various populations of cancer cells that are genetically different from one another (see Figure 1.8).

In fact, scientists analyzing multiple biopsies from a single tumor have found huge variations in the number, type, and chromosome location of genetic mutations in the cancer cells. One of the first and most




Figure 1.8 Genome instability drives intratumoral heterogeneity. (a) In a microscopic cluster of cancer cells, all the cells are likely to contain the same genetic faults. However, the cells are **genomically unstable** and likely to pick up more mutations. (b) The cells start to evolve and become different from one another. (c) As time goes on, the cells diverge from each other more and more, creating distinct populations of cells driven by different sets of mutations.